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The preparation of several new analogues of the natural dihydropyrone pironetin is described. 
They differ from the natural product mainly in the nature of the side chain and the lactone ring. 
Their cytotoxic activity has been measured. In addition, their interaction with tubulin and their 
ability to inhibit the secretion of the vascular endothelial growth factor (VEGF) and the expression 
of angiogenesis and telomerase-related genes have been determined. Some of the compounds have 
been found active in some of these biological properties.
Introduction 
It is widely known that cancer, one leading cause of death in 
developed countries, may be induced by a plethora of both 
external and internal factors, including genetic mutations. 
Accordingly, a number of types of therapeutic attack has been 
investigated.1 One of these involves the use of cytotoxic 
drugs, which exert their effect in many cases by means of 
inducing various mechanisms of cell death.2 As a matter of 
fact, many of such drugs owe this property to interaction with 
the microtubule network. Microtubules are dynamic polymers 
that play a central role in a number of cellular processes, most 
particularly cell division, as they are key constituents of the 
mitotic spindle.3 Microtubules are constituted of a protein 
named tubulin, the functional form of which, and the most 
abundant component, is a heterodimer formed through non-
covalent binding of two monomeric constituents, called - 
and -tubulin. For cell division to occur in a normal way, 
microtubules must be in a constant state of formation and 
disruption, a process named microtubule dynamic instability.4 
Molecules which influence microtubule instability will also 
influence the cell division process, not only of normal cells 
but also of tumoral ones. Therefore, it is not surprising that 
tubulin-binding molecules (TBMs) constitute a very important 
class of anticancer agents.5 
 
 TBM are able to interfere with microtubule assembly and 
functions, either by causing disruption of the microtubules or 
else through their stabilization. Most of the hitherto described 
active drugs are natural products or derivatives thereof.6 
Major drugs can already be found on the market and many 
other promising compounds are in clinical trials. 
 TBM may be divided in two broad categories, those that 
bind to -tubulin and those that bind to -tubulin. The latter 
group is presently by far the most numerous and contains 
products which cause either disruption7 or stabilization8 of 
microtubules. The number of products that bind to -tubulin 
is, however, very small,9 the naturally occurring 5,6-dihydro-
-pyrone pironetin (Figure 1) being the first-reported 
example. Pironetin is a potent inhibitor of tubulin assembly 
and has been found to arrest cell cycle progression in the 
G2/M phase.10 This feature has motivated a number of groups 
to undertake total syntheses of this natural compound.11 It is 
worth mentioning here that 5,6-dihydro--pyrones constitute 
an ample group of natural products endowed with a broad 
variety of pharmacologically useful properties, most likely 
related to the presence of the Michael acceptor moiety in the 
pyrone ring.12 
 
Figure 1  Structure of pironetin, a highly cytotoxic natural 
pyrone. 
 Some structure-activity (SAR) studies on pironetin have 
been reported.10 These studies have shown that the presence 
of the conjugated double bond in the lactone ring and of the 
hydroxyl group at C-9, either free or methylated, are essential 
for the biological activity.9 The epoxidation of the C12=C13 
double bond has been shown to cause a decrease in the 
activity but this may perhaps represent a negative feature of 
the oxirane ring, rather than a strict need of this C=C bond. 
 As a member of the up to now small group of products that 
bind to -tubulin, pironetin constitutes a pharmacologically 
interesting target. Thus, a key purpose of our research is the 
preparation of pironetin analogues that retain a substantial 
proportion of the biological activity of the natural metabolite 
while displaying a more simplified structure. In order to 
develop SAR studies based upon the pironetin framework, we 
designed several years ago13 a simplified model structure 
where all elements that had not yet proven to be essential for 
the biological activity were removed. The target structures 
I/II are schematically shown in Figure 2. The elements that 
were maintained are the conjugated dihydropyrone ring and 
the side chain with the methoxy group at C-9. The hydroxyl 
group at C-7 was removed in some substrates (I) and retained 
in others (II), in order to see its influence on the activity. All 
alkyl pendants (methyl groups at C-8 and C-10, ethyl at C-4) 
and the isolated C12−C13 double bond were removed. The 
  
configurations of the two/three remaining stereocentres were 
then varied in a systematic way. Thus, all four possible 
stereoisomers with general constitution I, with no hydroxyl 
group at C-7, were prepared. Likewise, all eight stereoisomers 
exhibiting general structure II, with a hydroxyl group at C-7, 
were synthesized. Subsequently, the cytotoxic activity of 
these analogues and their interactions with tubulin were 
investigated.13 
 
Figure 2  General structures of the first generation of 
simplified pironetin analogues (ref. 13). 
 In continuation of this line of research, we concentrated our 
attention on the importance of the alkyl pendants in the 
pironetin molecule for the biological properties of the natural 
compound. In line with this reasoning, we prepared the six 
pironetin analogues III-VIII (Fig. 3). In all these compounds, 
the configurations at the oxygenated carbons C-5, C-7 and C-9 
are as in natural pironetin. With respect to general structure II 
(Fig. 2), compounds III and IV contain an additional methyl 
residue at C-10 with either configuration, whereas in 
compounds V and VI, the extra methyl pendant is allocated at 
C-8. Finally, compounds VII and VIII display an extra alkyl 
residue (methyl or ethyl) at C-4, in both cases with the same 
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Figure 3  Structures III-VIII of the second series of pironetin 
analogues (ref. 13). 
 The cytotoxic activities of pironetin analogues III-VIII 
were then investigated. Most compounds proved cytotoxic in 
the low micromolar range, therefore about two-three orders of 
magnitude less active than pironetin itself.14 These results 
suggest that all alkyl pendants are important for the full 
biological activity, this being most likely due to the fact that 
the alkyl groups restrict the conformational mobility of the 
molecule and reduce the number of available 
conformations.15,16 This in turn makes more probable that the 
molecule adopts a shape that fits better into the active site of 
-tubulin. 
 In view of these results, we decided to prepare a new group 
of pironetin analogues with a higher degree of alkylation in 
the side chain but still retaining a simplified structure. Figure 
4 shows the eight compounds we have prepared and evaluated 
for their biological properties. 
 
Figure 4  Structures of compounds of the third series of 
pironetin analogues (this work). 
 In comparison to pironetin, pyrones 1, ent-1, 2 and ent-2 in 
Fig. 4 display a shorter carbon chain, two stereocentres less 
(C-4 and C-10 in pironetin numbering) and an additional gem-
dimethyl moiety (at C-6 in pironetin numbering). 
Furthermore, and in order to investigate the importance of the 
lactone ring size, analogues 3, ent-3, 4 and ent-4 having a 
furanone system were also prepared. 
 In recent times, we have not limited our biological 
investigations on bioactive molecules to solely measurements 
of their cytotoxic activity, expressed as IC50 values. Indeed, 
while mechanisms of anticancer activity are often related to 
interference with microtubule assembly and functions, other 
mechanisms may also be operative. In most solid tumors, for 
example, angiogenesis is an important process for tumor 
growth and metastasis. Many different mediators are involved 
in this process, including the vascular endothelial growth 
factor (VEGF), which has been shown to play a critical role in 
pathological angiogenesis.17 
 Another relevant mechanism in cancer genesis is related to 
the role of the chromosomal telomers. Most cancer cells 
exhibit telomerase activity. The latter mantains the length of 
the telomeres, thus preserving genomic stability.18 Telomerase 
is a ribonucleoprotein composed of two main subunits which, 
in the case of human beings, are called human telomerase 
RNA (hTR) and human telomerase protein (hTERT). Many 
studies have demonstrated that interference in the expression 
of the hTERT gene can efficiently inhibit the growth and 
tumorigenicity of cancer cells, as the hTERT gene is a rate-
  
limiting factor in telomerase synthesis and activity. Equally 
important is the c-Myc gene, which has been found to be 
amplified in various types of human cancers. The result of the 
expression of this gene, the c-Myc protein, is a transcriptional 
factor with an important role in cell proliferation, 
differentiation, invasion and adhesion of tumor cells.19 It is 
also involved in the activation of hTERT gene transcription. 
 Since on one hand tumoral cell secretion of VEGF is an 
important factor in metastasis and, on the other hand, 
telomerase is responsible for the inmortality of tumoral cells, 
the potential multiple ability20 of some compounds to perturb 
microtubule dynamics and, at the same time, to inhibit VEGF 
secretion by tumoral cells and the expression of the VEGF, 
hTERT and c-Myc genes was considered a goal worth 
pursuing. For that reason, we have also included the last types 
of biological activities in our unvestigation of the general 
pharmacological profile of our compounds. 
 
Results and discussion 
Synthesis of compounds 1-4 and their enantiomers 
For our purposes, we aimed at performing a simple synthetic 
sequence in which stereochemical complexity is rapidly 
achieved through a convergent methodology. Thus, the 
synthesis of compounds 1-4 was carried out as depicted in 
Scheme 1. Creation of chirality was achieved by means of an 
adaptation of a published organocatalytic procedure.21 Thus, 
propionaldehyde and isobutyraldehyde were allowed to react 
in DMF in the presence of D-proline. This gave a crossed 
aldol product which was subjected in situ to Barbier-type, 
indium-mediated prenylation to yield diol 5 in fair yield and 
high enantio- and diastereoselectivity.21 Methylation to 6 was 
followed by ozonolysis to yield an unstable intermediate 
aldehyde which, without isolation, was allowed to react with 
allylmagnesium bromide in THF. This sequence furnished a 
mixture of diastereoisomeric alcohols 7 and 8 (d.r. 2:1), which 
proved amenable to chromatographic separation. Both 
compounds were then esterified with acryloyl chloride, and 
the resulting acrylates, 9 and 10, were subjected to ruthenium-
catalyzed ring-closing metathesis22 to afford the target 
dihydropyranones 1 and 2, respectively. Their enantiomers 
ent-1 and ent-2 were obtained by means of an identical 
synthetic sequence with the only difference of using L-proline 
as the organocatalyst (see Experimental). 
 
Scheme 1  Synthesis of dihydropyranones 1 and 2. Abbreviations: D-
Pro, D-proline; DIPEA, ethyl N,N-diisopropylamine. 
 
Scheme 2  Synthesis of furanones 3 and 4. 
 Furanones 3 and 4 were prepared by means of a similar 
reaction sequence starting from olefin 6 (Scheme 2). Thus, the 
latter compound was subjected to ozonolysis followed by 
treatment of the crude unstable aldehyde with 
vinylmagnesium chloride to yield alcohols 11 and 12. These 
were then separated and subjected to esterification to acrylates 
13 and 14, respectively. Ring-closing metathesis of the latter 
compounds required the use of a second generation Grubbs 
ruthenium catalyst22 in hot toluene as the solvent, and 
provided the target furanones 3 and 4. Their enantiomers ent-3 
and ent-4 were obtained from ent-6 alongside the same 
reaction sequence (see Experimental). 
  
 
Scheme 3  Attempts at the synthesis of dihydropyranones 22 and 23 
and furanones 30 and 31. Abbreviation: 2,6-lut, 2,6-lutidine. 
 In order to check the influence of having hydroxy instead 
of methoxy groups in the side chain (pironetin and compounds 
in Fig. 3 have one methoxy group and one hydroxyl group), 
we also tried to prepare analogues of compounds 1-4 with two 
hydroxy groups. To that purpose, diol 5 was doubly silylated 
to 15, and the latter subjected to the same 
ozonolysis/allylation or alternatively ozonolysis/vinylation 
sequence to yield the diastereoisomeric pairs 16/18 and 24/26, 
respectively (Scheme 3). After esterification with acryloyl 
chloride to 17/19 and 25/27, ring-closing metathesis using in 
this case a Hoveyda-Grubbs-type ruthenium catalyst22 
afforded 20/21 and 28/29, respectively. Unfortunately, all 
attempts at desilylation of the latter compounds under many 
different conditions to the desired lactones 22, 23, 30 and 31 
only led to either no reaction, decomposition or formation of 
complex inseparable mixtures.23 
Biological properties of pironetin analogues 1-4 and their 
enantiomers 
Cellular effects of the compounds. We have determined the 
IC50 values for pironetin analogues 1-4, and ent-1/ent-4 on five 
tumoral cell lines: human colorectal adenocarcinoma HT-29 and 
HTC-116, human breast adenocarcinoma MCF-7, human cervical 
cancer HeLa and human promyelocytic leukemia HL-60, and 
compared these values with that of pironetin. Table 1 shows the 
cytotoxicity values for pironetin (nM) and pironetin analogues 
expressed as the compound concentration (µM) that causes 50% 
inhibition of cell growth (IC50). 
Table 1. IC50 values (M) 
Comp HT-29 HTC-116 MCF-7 HeLa HL-60 
Piron. 7.1± 0,4 nM 8.3± 0.5 nM  6.8± 0,6 nM 9.2± 0.8 nM 12.6± 0.9 nM
1 4.2 ± 0.4 30 ± 1 22.25 ± 0.18 38 ± 3 3.4 ± 0.7 
2 28.5 ± 0.5 62 ± 2 21 ± 2 60.5 ± 0.3 4.0 ± 0.5 
3 >100 >100 >100 95 ± 5 >100 
4 >100 >100 >100 >100 >100 
ent1 47 ± 2 62.0 ± 0.6 50 ± 2 54.2 ± 0.4 33 ± 7 
ent-2 5.9 ± 0.8 36 ± 1 12.9 ± 0.9 53.8 ± 0.1 1.38 ± 0.15 
ent-3 >100 >100 >100 >100 >100 
ent-4 >100 >100 >100 >100 >100 
aIC50 values (M for 1-4, and ent-1/ent-4 and nM for pironetin) are the 
mean ± standard error of three independent experiments. 
 The first conclusion that can be drawn from the IC50 values 
is that furanones 3 and 4 and their respective enantiomers ent-
3 and ent-4 show almost no cytotoxicity. Pyranones did prove 
cytotoxic in the low micromolar range, thus about two-three 
orders of magnitude less active than pironetin itself. Among 
pyranones the most active compounds are 1 and ent-2. These 
two compounds share a common structural feature, the 
configuration of the lactone stereocenter, which is the same as 
in pironetin. 
Effect of pironetin derivatives on the in vitro microtubule 
assembly. As pyranone derivatives showed to be cytotoxic we 
selected them to study their effect on the in vitro microtubule 
assembly. Figure 5 shows the effects of pyranones 1, 2, ent-1 and 
ent-2 on the microtubule formation studied by time-resolved 
turbidity measurements. Blue line shows the effects on the 
  
microtubule assembly when 25 µM of tubulin was reacted in the 
presence of 20 mM sodium phosphate (NaPi), 10 mM MgCl2, 1 
mM EGTA, 3.4 M glycerol and 0.1 mM of GTP at pH=6.5. It can 
be seen that the nucleation phase takes aproximately 18 min. 
Then elongation phase starts and after 20 min the steady state is 
reached. When tubulin assembly is carried out in the presence of 
27.5 µM of paclitaxel, absorbance is immediately increased 
(orange line) which is in accordance with the behaviour of a drug 
that promotes tubulin polymerization. Conversely, when tubulin 
assembly is carried out in the presence of 27.5 µM of pironetin, 
no absorbance is measured throughout the reaction time (green 
line), which is in accordance with the behaviour of a drug that 
inhibits tubulin polymerization. When tubulin assembly is carried 
out in the presence of 27.5 µM of each pyranone the dinamic of 
microtubule formation is quite similar to the one in the ausence of 
any compound (blue line). It can be inferred from these 
experiments that, in contrast to pironetin itself, pyranones 1, 2, 
ent-1 and ent-2 have little influence on the process of tubulin 
polymerization. 
 
Figure 5.. Effects of colchicine, pironetine and compounds 1, 2, ent-1 and 
ent-2, as well as paclitaxel and pironetin, on the in vitro microtubule 
assembly. The lines in the figure show the turbidimetric time course of 
polymerization of tubulin in the presence of GTP, and in the presence of 
27.5 µM of each of the indicated compound. 
Effect of pyranone derivatives on the hTERT, c-Myc and VEGF 
gene inhibition and on the VEGF protein secretion. We have also 
studied the ability of pyranones 1, 2, ent-1 and ent-2 to 
downregulate the expression of the hTERT and c-Myc genes, both 
involved in telomerase activity, and the expression of the VEGF 
gene and its associated protein VEGF, both involved in 
angiogenic activity. The expression of hTERT, c-Myc and VEGF 
genes were measured upon reverse transcription quantitative PCR 
(RT-qPCR) analysis on HT-29 tumoral cells. The VEGF protein 
production was determined with the ELISA procedure and 
corresponds mainly to the lighter VEGFA-165 isoform that is 
secreted to the culture medium. Table 2 shows expression 
percentage of the hTERT, c-Myc and VEGF genes after 48 h of 
incubation of HT-29 cells. Table 2 also shows VEGF protein 
secretion percentage from HT-29 cells determined after 72 h of 
incubation of HT-29 cells. 
Table 2. Percentages of gene expression and VEGF protein 
secretion 
Comp. Concent. hTERTa 
(%) 




1 5 M 49 ± 4 18 ± 1 45 ± 5 29 ± 4 
2 25 M 42 ± 7 25 ± 2 26 ± 1 36 ± 2 
ent-1 25 M 59 ± 8 36.5 ± 1.5 36 ± 2 63 ± 7 
ent-2 5 M 39 ± 5 25 ± 4 19.0 ±0.2 76 ± 4 
aAt least three measurements were performed in each case. 
 As regards the inhibition of the hTERT and c-Myc genes, 
compounds 1 and ent-2 are the most active ones, especially if 
one considers that the concentration of these two compounds 
is five times lower than that of compounds 2 and ent-1. 
Particularly appealing is the activity of compound 1 on the 
inhibition in the expression of the c-Myc gene, which is 
decreased to 18% of the control value. Regarding the VEGF 
gene expression compound ent-2 shows the greatest 
inhibition. However, this high decrease in gene expression is 
not accompanied by a similar decrease in VEGF protein 
secretion as compound ent-2 downregulates protein secretion 
by only 24%. In this sense, the most active compound is 
pyranone 1 which downregulates VEGF protein secretion by 
71%. 
Summary 
Pironetin analogues 1-4 and their enantiomers were 
synthesized with the aim at exploring the influence of the alkyl 
pendants as well as their stereochemistry and lactone ring size in 
their biological activity. Pyranones showed to be cytotoxic at 
micromolar level while furanones showed no cytotoxicity. 
Among pyranones the most cytotoxic were 1 and ent-2, which 
have the same configuration at the lactone stereocenter as 
pironetin. The influence of pyranones in tubulin polymerization 
was also measured but, in contrast to pironetin, they seem to have 
little influence in the tubulin polymerization process. It thus 
seems that removal of the methyl pendants at the side chain by a 
gem-dimethylated pattern causes a strong decrease in the 
interaction of the compounds with tubulin. As regards the 
inhibition of the c-Myc and VEGF genes, pyranones 1 and ent-2 
proved to be the most active compounds with 1 showing the 
strongest inhibition of VEGF protein secretion. 
Experimental 
Chemical procedures 
NMR spectra were recorded at 500 MHz (1H NMR) and 125 
MHz (13C NMR) in CDCl3 solution at 25 C, with the solvent 
signals as internal reference. 13C NMR signal multiplicities were 
determined with the APT pulse sequence. Mass spectra were run 
in the electrospray (ESMS) mode. IR data, which were measured 
as films on NaCl plates (oils) or as KBr pellets (solids), are given 
only when relevant functions (C=O, OH) are present. Optical 
rotations were measured at 25 C. Reactions which required an 
inert atmosphere were carried out under dry N2 with flame-dried 
glassware. Commercial reagents were used as received. THF and 
Et2O were freshly distilled from sodium-benzophenone ketyl. 
Dichloromethane was freshly distilled from CaH2. Toluene was 
freshly distilled from sodium wire. Tertiary amines were freshly 
distilled from KOH. 
(3R,4R,5R)-2,4,6,6-Tetramethyloct-7-ene-3,5-diol (5). The 
following reaction conditions should be strictly adhered to, with 
particular attention to the words highlighted in italics: D-proline 
(230 mg, 2 mmol) was dissolved under N2 in dry DMF (2 mL) 
and placed in an ice bath. After stirring for 5 minutes, freshly 
distilled isobutyraldehyde (1.82 mL, 20 mmol) was added 


















followed by dry DMF (2.5 mL). In a separate flask, freshly 
distilled propionaldehyde (722 L, 10 mmol) was dissolved in 
dry DMF (7 mL). The resulting solution was ice-cooled and 
added dropwise to the isobutyraldehyde solution by means of 
syringe pump at a rate of 0.10 mL/h (the needle of the pump 
should be just below the surface of the liquid). Caution: higher 
addition rates give rise to diminished yields! When all the 
propionaldehyde solution had been added, the reaction mixture 
was stirred at the same temperature for 15 h. Subsequently, 
prenyl bromide (2.31 mL, 20 mmol) was added dropwise (ca. 10 
min.) followed by sodium iodide (1.65 g, 11 mmol) and 
powdered metallic indium (1.27 g, 11 mmol). The mixture was 
then very vigorously stirred for 5 min. at 0 ºC. After allowing the 
mixture to reach room temperature, water (11 mL) was added and 
the stirring was continued for 48 h. The reaction mixture was then 
poured onto saturated ammonium chloride and carefully extracted 
with EtOAc (caution, emulsions may be formed!). The organic 
layers were then dried over anhydrous MgSO4, filtered and 
evaporated under reduced pressure. The resulting oil was 
carefully chromatographed on silica gel (hexane-EtOAc, from 
95:5 to 80:20). This yielded diol 5 (801 mg, 40% based on 
propionaldehyde) as off-white crystals (from Et2O-CHCl3): mp 
76-77 ºC (from Et2O-CH2Cl2), []D +17.6 (c 1; CHCl3). Spectral 
data were consistent with those published17 (see Electronic 
Supplementary Information). 
The procedure described above represents the maximum scale 
at which we were able to obtain reasonable yields. Attempts at 
increasing the scale only led to a decrease in the yield. 
The procedure was repeated under the same conditions with L-
proline to yield ent-5: []D −18.1 (c 1; CHCl3). Physical and 
spectral data identical to those of 5. 
The stereostructures of 5 and ent-5 have been secured by means 
of an X-ray diffraction analysis.24 
(4R,5R,6R)-4,6-Dimethoxy-3,3,5,7-tetramethyloct-1-ene 
(6). Sodium hydride (60% slurry in mineral oil, amount 
equivalent to 16 mmol) was washed two times under N2 with 
dry hexane and once with dry THF. Then, THF (50 mL) was 
added and the suspension was cooled in an ice bath. Alcohol 5 
(801 mg, 4 mmol) was then dissolved in dry THF (10 mL) and 
added dropwise to the sodium hydride suspension. The 
mixture was then allowed to reach room temperature. 
Subsequently, methyl iodide (1.25 mL, 20 mmol) was added 
dropwise and the mixture was stirred for 24 h at room 
temperature. The reaction mixture was then poured onto 
saturated ammonium chloride and extracted several times with 
Et2O. The organic layers were then dried over anhydrous Na2SO4, 
filtered and evaporated under reduced pressure. The resulting oil 
was carefully chromatographed on silica gel (hexane-EtOAc, 
95:5). This yielded 6 (822 mg, 90%): oil, []D +1.8 (c 1; CHCl3); 
1H NMR  5.99 (1H, dd, J = 17.5, 11 Hz), 4.98 (1H, dd, J = 17.5, 
1.5 Hz), 4.94 (1H, dd, J = 11, 1.5 Hz), 3.44 (3H, s), 3.38 (3H, s), 
3.06 (1H, dd, J = 6, 3.5 Hz), 2.88 (1H, d, J = 5 Hz), 1.98 (1H, m), 
1.88 (1H, br m), 1.08 (3H, s), 1.07 (3H, s), 0.99 (3H, d, J = 7.5 
Hz), 0.93 (3H, d, J = 7 Hz), 0.90 (3H, d, J = 7 Hz); 13C NMR  
43.2 (C), 146.6, 91.6, 86.9, 38.8, 30.3 (CH), 110.8 (CH2), 61.4, 
59.5, 25.7, 23.3, 22.0, 17.1, 16.4 (CH3); HR ESMS m/z 251.1991 
(M+Na+), calcd. for C14H28NaO2, 251.1987. 
(ent-6): oil, []D 1.8 (c 1; CHCl3). Physical and spectral data 
identical to those of 6. 
(4S,6R,7R,8R)-6,8-Dimethoxy-5,5,7,9-tetramethyldec-1-en-
4-ol (7) and (4R,6R,7R,8R)-6,8-dimethoxy-5,5,7,9-tetra-
methyldec-1-en-4-ol (8). Olefin 6 (685 mg, 3 mmol) was 
dissolved in dry CH2Cl2 (60 mL) and cooled to 78C. A 
stream of ozone-oxygen was bubbled through the solution 
until persistence of the bluish color. Dry N2 was then bubbled 
through the solution for 10 min. at the same temperature. 
After addition of PPh3 (1.18 g, 4.5 mmol), the solution was 
left to stir at room temperature for 2 h. Solvent removal under 
reduced pressure gave a solid material, which was put on the 
top of a short silica gel pad and rapidly washed with hexane-
EtOAc 9:1. After removal of volatiles under reduced pressure, 
the crude oily aldehyde was then directly used as such in the 
next allylation step (for weight calculations, the yield of the 
ozonolysis step was assumed to be quantitative). 
The oily material from above was dissolved under N2 in dry 
THF (15 mL) and cooled in an ice bath. After this, a 1 M 
solution of allylmagnesium bromide in THF (4 mL, 4 mmol) 
was added dropwise, and the mixture was allowed to reach 
room temperature, followed by stirring for 3 h (TLC 
monitoring). The reaction mixture was then poured onto 
saturated ammonium chloride and extracted several times with 
Et2O. The organic layers were then dried over anhydrous Na2SO4, 
filtered and evaporated under reduced pressure. The resulting oil 
was the subjected to a slow and careful chromatography on silica 
gel (hexane-Et2O, 9:1) to yield 7 (367 mg, 45%) and 8 (182 g, 
22%). 
(7): oil, []D 23.3 (c 1; CHCl3); IR max (cm-1): 3400 (br, OH); 
1H NMR  5.90 (1H, ddt, J = 17, 10.5, 7 Hz), 5.01 (1H, dm, J  
17 Hz), 4.94 (1H, dm, J  10.5 Hz), 4.90 (1H, br d, J  3 Hz, 
OH), 3.68 (1H, dt, J = 10, 3 Hz), 3.45 (6H, s), 3.02 (1H, dd, J = 
10, 1 Hz), 2.74 (1H, d, J = 2.5 Hz), 2.38 (1H, m), 2.14 (1H, m), 
2.04 (1H, m), 1.81 (1H, m), 0.99 (3H, d, J = 7 Hz), 0.90 (3H, d, J 
= 7.5 Hz), 0.89 (3H, s), 0.87 (3H, s), 0.80 (3H, d, J = 7 Hz); 13C 
NMR  43.4 (C), 137.9, 97.1, 87.3, 73.0, 36.2, 30.3 (CH), 115.1, 
35.9 (CH2), 62.0, 60.3, 25.5, 22.2, 21.1, 17.2, 14.5 (CH3); HR 
ESMS m/z 273.2429 (M+H+), calcd. for C16H33O3, 273.2430. 
(ent-7): oil, []D +21.5 (c 1; CHCl3). Physical and spectral data 
identical to those of 7. 
(8): oil, []D +9.5 (c 1; CHCl3); IR max (cm-1): 3480 (br, OH); 1H 
NMR  5.94 (1H, ddt, J = 17, 10.5, 7 Hz), 5.08 (1H, dm, J  17 
Hz), 5.04 (1H, dm, J  10.5 Hz), 3.70 (2H, m), 3.47 (3H, s), 3.41 
(3H, s), 3.02 (2H, m), 2.22 (1H, m), 2.10 (2H, m), 1.90 (1H, m), 
1.03 (3H, d, J = 7.5 Hz), 0.99 (3H, s), 0.98 (3H, d, J = 7 Hz), 0.90 
(3H, d, J = 7 Hz), 0.88 (3H, s); 13C NMR  42.9 (C), 137.4, 95.1, 
86.8, 75.7, 37.0, 30.5 (CH), 115.9, 36.7 (CH2), 61.9, 59.9, 22.5, 
21.7, 21.0, 19.7, 16.0 (CH3); HR ESMS m/z 273.2430 (M+H+), 
calcd. for C16H33O3, 273.2430. 
(ent-8): oil, []D 11.8 (c 1; CHCl3). Physical and spectral data 
identical to those of 8. 
(4S,6R,7R,8R)-6,8-Dimethoxy-5,5,7,9-tetramethyldec-1-en-
4-yl acrylate (9) and (4R,6R,7R,8R)-6,8-dimethoxy-5,5,7,9-
tetramethyldec-1-en-4-yl acrylate (10). Alcohol 7 or 8 (82 
mg, 0.3 mmol) was dissolved under N2 in dry CH2Cl2 (5 mL), 
  
cooled to 78C and treated sequentially with ethyl N,N-
diisopropylamine (160 L, 0.9 mmol) and acryloyl chloride 
(50 L, 0.6 mmol). The reaction mixture was then stirred for 3 
h at 78C. The reaction mixture was then poured onto saturated 
ammonium chloride and extracted several times with CH2Cl2. 
The organic layers were then dried over anhydrous MgSO4, 
filtered and evaporated under reduced pressure. The resulting oil 
was the subjected in each case to chromatography on silica gel 
(hexane-EtOAc, 98:2) to afford 9 (81 mg, 83%) and 10 (80 mg, 
82%), respectively. 
(9): oil, []D +6.8 (c 1; CHCl3); IR max (cm-1): 1724 (C=O); 1H 
NMR  6.38 (1H, dd, J = 17.5, 1.5 Hz), 6.10 (1H, dd, J = 17.5, 
10.5 Hz), 5.79 (1H, dd, J = 10.5, 1.5 Hz), 5.75 (1H, m), 5.20 (1H, 
dd, J = 10, 2.5 Hz), 5.02 (1H, br dd, J = 17, 1.5 Hz), 4.97 (1H, br 
dd, J ~ 10, 1.5 Hz), 3.43 (3H, s), 3.39 (3H, s), 3.05-3.00 (2H, m), 
2.59 (1H, m), 2.24 (1H, m), 2.04 (1H, d quint, J = 7, 4 Hz), 1.90 
(1H, d quint, J = 7, 2.5 Hz), 1.02 (3H, d, J = 7.5 Hz), 0.98 (3H, d, 
J = 7.5 Hz), 0.96 (3H, s), 0.95 (3H, s), 0.90 (3H, d, J = 7 Hz); 13C 
NMR  165.8, 43.6 (C), 135.6, 128.9, 90.2, 86.4, 77.7, 37.5, 30.5 
(CH), 130.1, 116.7, 35.5 (CH2), 60.9, 59.7, 21.7, 20.8, 20.3, 18.8, 
16.1 (CH3); HR ESMS m/z 349.2359 (M+Na+), calcd. for 
C19H34NaO4, 349.2355. 
(ent-9): oil, []D 9.1 (c 1; CHCl3). Physical and spectral data 
identical to those of 9. 
(10): oil, []D 22.8 (c 1; CHCl3); IR max (cm-1): 1726 (C=O); 
1H NMR  6.38 (1H, dd, J = 17.5, 1.5 Hz), 6.11 (1H, dd, J = 17.5, 
10.5 Hz), 5.80 (1H, dd, J = 10.5, 1.5 Hz), 5.76 (1H, m), 5.23 (1H, 
dd, J = 10, 3 Hz), 5.01 (1H, br dd, J = 17, 1.5 Hz), 4.97 (1H, br 
dd, J ~ 10, 1.5 Hz), 3.39 (3H, s), 3.33 (3H, s), 3.02 (1H, dd, J = 
8.5, 2 Hz), 2.94 (1H, d, J = 3.5 Hz), 2.45 (1H, m), 2.24 (1H, m), 
1.98 (1H, d quint, J = 6.5, 3.5 Hz), 1.89 (1H, d quint, J = 7, 2.5 
Hz), 1.02 (3H, d, J = 7 Hz), 0.97 (3H, d, J = 7 Hz), 0.96 (3H, s), 
0.94 (3H, s), 0.88 (3H, d, J = 6.5 Hz); 13C NMR  165.8, 43.4 
(C), 135.5, 129.1, 88.3, 86.2, 76.8, 37.6, 30.5 (CH), 130.1, 116.8, 
35.1 (CH2), 60.7, 59.8, 21.7, 19.1, 19.0, 18.5, 15.6 (CH3); HR 
ESMS m/z 349.2360 (M+Na+), calcd. for C19H34NaO4, 349.2355. 
(ent-10): oil, []D +17.8 (c 1; CHCl3). 
(6S)-[(3R,4R,5R)-3,5-Dimethoxy-2,4,6-trimethylheptan-2-
yl]-5,6-dihydro-2H-pyran-2-one (1) and (6R)-[(3R,4R,5R)-
3,5-dimethoxy-2,4,6-trimethylheptan-2-yl]-5,6-dihydro-
2H-pyran-2-one (2). Diolefin 9 or 10 (65 mg, 0.2 mmol) was 
dissolved under N2 in dry, degassed CH2Cl2 (20 mL) and 
treated with Grubbs first-generation ruthenium catalyst Ru-I 
(16 mg, ca. 0.02 mmol). The mixture was heated at reflux 
until consumption of the starting material (2-3 h, TLC 
monitoring!). Removal of volatiles under reduced pressure 
and column chromatography of the residue on silica gel 
(hexane-EtOAc 9:1) furnished the desired metathesis products 
1 (57 mg, 97%) and 2 (56 mg, 96%), respectively. 
(1): oil, []D െ78.2 (c 1.05; CHCl3); IR max (cm-1): 1725 (C=O); 
1H NMR  6.92 (1H, ddd, J = 9.5, 6.5, 2.5 Hz), 6.00 (1H, dd, J = 
9.5, 2 Hz), 4.38 (1H, dd, J = 12.5, 3.5 Hz), 3.42 (3H, s), 3.39 (3H, 
s), 3.20 (1H, d, J = 3 Hz), 3.00 (1H, dd, J = 8, 3 Hz), 2.49 (1H, 
ddt, J = 18, 12.5, 2.5 Hz), 2.36 (1H, ddd, J = 18, 6.5, 3.5 Hz), 
2.00-1.85 (2H, m), 1.02 (3H, d, J = 7 Hz), 0.97 (3H, d, J = 7 Hz), 
0.91 (3H, s), 0.86 (3H, d, J = 7 Hz), 0.85 (3H, s); 13C NMR  
164.9, 42.7 (C), 146.3, 121.1, 89.6, 86.3, 82.7, 37.3, 30.4 (CH), 
25.4 (CH2), 61.1, 59.8, 21.7, 20.3, 19.8, 19.1, 15.7 (CH3); HR 
ESMS m/z 321.2040 (M+Na+), calcd. for C17H30NaO4, 321.2042. 
(ent-1): oil, []D +71.4 (c 1; CHCl3). Physical and spectral data 
identical to those of 1. 
(2): off-white solid, mp 67-69 ºC (from Et2O-CH2Cl2), []D 
െ10.6 (c 1; CHCl3); IR max (cm-1): 1727 (C=O); 1H NMR  6.93 
(1H, ddd, J = 9.5, 6.5, 2 Hz), 6.00 (1H, dd, J = 9.5, 2 Hz), 4.58 
(1H, dd, J = 13, 3.5 Hz), 3.43 (3H, s), 3.37 (4H overall, an OMe 
singlet overlapping an one-proton signal), 2.99 (1H, dd, J = 8, 2.5 
Hz), 2.37 (1H, ddt, J = 18, 13, 2.5 Hz), 2.25 (1H, ddd, J = 18, 6.5, 
3.5 Hz), 1.90-1.80 (2H, m), 1.02 (3H, d, J = 7 Hz), 0.97 (3H, d, J 
= 7 Hz), 0.91 (3H, s), 0.86 (3H, d, J = 7 Hz), 0.85 (3H, s); 13C 
NMR  164.8, 42.5 (C), 146.1, 121.1, 87.4, 86.2, 81.1, 37.2, 30.4 
(CH), 24.4 (CH2), 61.1, 59.8, 21.7, 19.8, 18.2, 17.4, 15.5 (CH3); 
HR ESMS m/z 321.2040 (M+Na+), calcd. for C17H30NaO4, 
321.2042. 
(ent-2): off-white solid, []D +6.1 (c 1; CHCl3). Physical and 
spectral data identical to those of 2. 
The stereostructures of 2 and ent-2 have been secured by means 
of an X-ray diffraction analysis.24 
(3S,5R,6R,7R)-5,7-Dimethoxy-4,4,6,8-tetramethylnon-1-en-
3-ol (11) and (3R,5R,6R,7R)-5,7-dimethoxy-4,4,6,8-tetra-
methylnon-1-en-3-ol (12). Olefin 6 (685 mg, 3 mmol) was 
dissolved in dry CH2Cl2 (60 mL) and cooled to 78C. A 
stream of ozone-oxygen was bubbled through the solution 
until persistence of the bluish color. Dry N2 was then bubbled 
through the solution for 10 min. at the same temperature. 
After addition of PPh3 (1.18 g, 4.5 mmol), the solution was 
left to stir at room temperature for 2 h. Solvent removal under 
reduced pressure gave a solid material, which was put on the 
top of a short silica gel pad and rapidly washed with hexane-
EtOAc 9:1. After removal of volatiles under reduced pressure, 
the crude oily aldehyde was then directly used as such in the 
next allylation step (for weight calculations, the yield of the 
ozonolysis step was assumed to be quantitative). 
The oily material from above was dissolved under N2 in dry 
THF (15 mL) and cooled in an ice bath. After this, a 1.6 M 
solution of vinylmagnesium chloride in THF (2.5 mL, 4 
mmol) was added dropwise, and the mixture was allowed to 
reach room temperature, followed by stirring for 2 h (TLC 
monitoring). The reaction mixture was then poured onto 
saturated ammonium chloride and extracted several times with 
Et2O. The organic layers were then dried over anhydrous Na2SO4, 
filtered and evaporated under reduced pressure. The resulting oil 
was the subjected to a slow and careful chromatography on silica 
gel (hexane-Et2O, from 98:2 to 95:5) to yield 11 (255 mg, 33%) 
and 12 (240 mg, 31%). 
(11): oil, []D 26.4 (c 1; CHCl3); IR max (cm-1): 3380 (br, OH); 
1H NMR  5.85 (1H, ddd, J = 17, 10.5, 6.5 Hz), 5.22 (1H, br d, J 
 17 Hz), 5.20 (1H, br s, OH), 5.09 (1H, br d, J ~ 10.5 Hz), 4.17 
(1H, m), 3.47 (6H, s), 3.05 (1H, dd, J = 10, 1.5 Hz), 2.80 (1H, br 
d, J ~ 3 Hz), 2.38 (1H, m), 1.83 (1H, m), 1.00 (3H, s), 0.91 (3H, 
d, J = 7.5 Hz), 0.88 (3H, s), 0.85 (3H, s), 0.81 (3H, d, J = 7 Hz); 
13C NMR  43.1 (C), 138.0, 96.5, 87.2, 75.1, 36.2, 30.3 (CH), 
115.3 (CH2), 61.9, 60.3, 25.6, 22.0, 21.1, 17.1, 14.5 (CH3); HR 
ESMS m/z 281.2094 (M+Na+), calcd. for C15H30NaO3, 281.2093. 
  
(ent-11): oil, []D +22.4 (c 1; CHCl3). Physical and spectral data 
identical to those of 11. 
(12): oil, []D +17.9 (c 1; CHCl3); IR max (cm-1): 3450 (br, OH); 
1H NMR  5.90 (1H, ddd, J = 17, 10.5, 6 Hz), 5.27 (1H, br d, J  
17 Hz), 5.15 (1H, br d, J ~ 10.5 Hz), 4.11 (1H, m), 3.95 (1H, br 
d, J  4 Hz, OH), 3.45 (3H, s), 3.41 (3H, s), 3.08 (1H, d, J = 4 
Hz), 3.01 (1H, d, J = 8.5, 2 Hz), 2.06 (1H, m), 1.89 (1H, m), 1.03 
(3H, d, J = 7 Hz), 0.98 (3H, d, J = 7 Hz), 0.96 (3H, s), 0.89 (3H, 
s), 0.88 (3H, d, J = 7 Hz); 13C NMR  42.6 (C), 138.0, 94.4, 86.7, 
78.4, 37.1, 30.4 (CH), 115.9 (CH2), 61.4, 60.0, 22.3, 21.6, 21.2, 
19.6, 15.6 (CH3); HR ESMS m/z 281.2095 (M+Na+), calcd. for 
C15H30NaO3, 281.2093. 
(ent-12): oil, []D 16.9 (c 1; CHCl3). Physical and spectral data 
identical to those of 12. 
(3S,5R,6R,7R)-5,7-Dimethoxy-4,4,6,8-tetramethylnon-1-en-
3-yl acrylate (13) and (3R,5R,6R,7R)-5,7-dimethoxy-4,4,6,8-
tetramethylnon-1-en-3-yl acrylate (14). Alcohol 11 or 12 
were subjected to esterification with acryloyl chloride under 
the same conditions used for the preparation of 9 and 10. In 
this way, acrylates 13 (85%) and 14 (84%) were obtained. 
(13): oil, []D 20.7 (c 1; CHCl3); IR max (cm-1): 1728 (C=O); 
1H NMR  6.42 (1H, dd, J = 17.5, 1.5 Hz), 6.15 (1H, dd, J = 17.5, 
10.5 Hz), 5.90 (1H, ddd, J = 17.5, 10.5, 7 Hz), 5.83 (1H, dd, J = 
10.5, 1.5 Hz), 5.37 (1H, br d, J ~ 7 Hz), 5.30-5.20 (2H, m), 3.41 
(3H, s), 3.40 (3H, s), 3.07 (1H, d, J = 3.5 Hz), 3.03 (1H, dd, J = 8, 
2 Hz), 2.00 (1H, d quint, J = 7, 3.5 Hz), 1.88 (1H, d quint, J = 7, 
2.5 Hz), 1.03 (3H, d, J = 8 Hz), 1.02 (3H, s), 0.95 (3H, d, J = 8 
Hz), 0.94 (3H, s), 0.88 (3H, d, J = 6.5 Hz); 13C NMR  165.3, 
43.5 (C), 133.8, 128.9, 88.9, 86.2, 79.7, 37.5, 30.5 (CH), 130.4, 
118.2 (CH2), 60.4, 59.8, 21.7, 19.8 (x 2), 18.6, 15.7 (CH3); HR 
ESMS m/z 335.2201 (M+Na+), calcd. for C18H32NaO4, 335.2198. 
(ent-13): oil, []D +20.8	(c 1; CHCl3). Physical and spectral data 
identical to those of 13. 
(14): oil, []D +16.7 (c 1; CHCl3); IR max (cm-1): 1729 (C=O); 
1H NMR  6.42 (1H, dd, J = 17.5, 1.5 Hz), 6.16 (1H, dd, J = 17.5, 
10.5 Hz), 5.90-5.80 (2H, m), 5.42 (1H, br d, J ~ 7 Hz), 5.30-5.20 
(2H, m), 3.41 (3H, s), 3.31 (3H, s), 3.06 (1H, d, J = 3 Hz), 3.03 
(1H, dd, J = 8, 2 Hz), 1.93 (1H, d quint, J = 7, 3.5 Hz), 1.85 (1H, 
d quint, J = 7, 2.5 Hz), 1.00 (3H, d, J = 7 Hz), 0.94 (3H, d, J = 7.5 
Hz), 0.91 (3H, s), 0.89 (3H, s), 0.84 (3H, d, J = 7 Hz); 13C NMR 
 165.2, 42.8 (C), 133.4, 128.9, 87.7, 86.2, 78.6, 37.5, 30.4 (CH), 
130.3, 118.3 (CH2), 60.5, 59.8, 21.6, 18.7, 18.6 (x 2), 15.5 (CH3); 
HR ESMS m/z 335.2198 (M+Na+), calcd. for C18H32NaO4, 
335.2198. 
(ent-14): oil, []D 17.2 (c 1; CHCl3). Physical and spectral data 
identical to those of 14. 
(5S)-[(3R,4R,5R)-3,5-Dimethoxy-2,4,6-trimethylheptan-2-
yl]furan-2(5H)-one (3) and (5R)-[(3R,4R,5R)-3,5-
dimethoxy-2,4,6-trimethylheptan-2-yl]furan-2(5H)-one (4). 
Diolefin 13 or 14 (62 mg, 0.2 mmol) was dissolved under N2 
in dry, degassed toluene (20 mL) and treated with Grubbs 
second-generation ruthenium catalyst Ru-II (17 mg, ca. 0.02 
mmol). The mixture was then heated at 80 ºC for 36 h. An 
addditional amount of ruthenium catalyst (10 mg) was added 
and the heating was continued until consumption of the 
starting material (ca. 3 d overall, TLC monitoring!). Removal 
of volatiles under reduced pressure and column 
chromatography of the residue on silica gel (hexane-EtOAc 
9:1) furnished the desired metathesis products 3 (48 mg, 85%) 
and 4 (45 mg, 79%), respectively. 
(3): oil, []D 98.3 (c 1; CHCl3); IR max (cm-1): 1758 (C=O); 1H 
NMR  7.61 (1H, dd, J = 6, 1.5 Hz), 6.01 (1H, dd, J = 6, 2 Hz), 
5.00 (1H, dd, J = 2, 1.5 Hz), 3.39 (3H, s), 3.31 (3H, s), 2.99 (1H, 
dd, J = 9.5, 2.5 Hz), 2.94 (1H, d, J = 3.5 Hz), 2.00 (1H, m), 1.89 
(1H, m), 1.07 (3H, s), 1.04 (3H, d, J = 7.5 Hz), 0.99 (3H, d, J = 
7.5 Hz), 0.94 (3H, s), 0.86 (3H, d, J = 7 Hz); 13C NMR  173.6, 
44.3 (C), 157.3, 119.4, 89.6, 88.8, 86.1, 37.3, 30.4 (CH), 60.3, 
60.0, 21.4, 21.1, 20.8, 19.0, 15.3 (CH3); HR ESMS m/z 307.1882 
(M+Na+), calcd. for C16H28NaO4, 307.1885. 
(ent-3): off-white solid, []D +91 (c 1; CHCl3). Physical and 
spectral data identical to those of 3. 
(4): off-white solid, mp 57-59 ºC (from Et2O-CH2Cl2), []D +47 
(c 1; CHCl3); IR max (cm-1): 1759 (C=O); 1H NMR  7.50 (1H, 
dd, J = 6, 1.5 Hz), 6.10 (1H, dd, J = 6, 2 Hz), 5.17 (1H, dd, J = 2, 
1.5 Hz), 3.47 (3H, s), 3.37 (3H, s), 3.22 (1H, d, J = 4 Hz), 2.97 
(1H, dd, J = 8, 2.5 Hz), 1.90-1.80 (2H, m), 1.00 (3H, d, J = 7 Hz), 
0.97 (3H, s), 0.93 (3H, d, J = 7 Hz), 0.84 (3H, d, J = 7 Hz), 0.69 
(3H, s); 13C NMR  173.2, 43.5 (C), 155.8, 122.2, 88.9, 87.8, 
86.1, 37.2, 30.4 (CH), 60.8, 59.8, 21.5, 19.4, 17.9, 17.6, 15.3 
(CH3); HR ESMS m/z 307.1888 (M+Na+), calcd. for C16H28NaO4, 
307.1885. 
(ent-4): off-white solid, []D െ47.4 (c 1; CHCl3). Physical and 
spectral data identical to those of 4. 
The stereostructures of 4 and ent-4 have been secured by means 
of an X-ray diffraction analysis.24 
(5R,6R,7R)-5-Isopropyl-2,2,3,3,6,9,9,10,10-nonamethyl-7-
(2-methylbut-3-en-2-yl)-4,8-dioxa-3,9-disilaundecane (15). 
Alcohol 5 (800 mg, 4 mmol) was dissolved under N2 in dry 
CH2Cl2 (25 mL) and treated sequentially with 2,6-lutidine (1.4 
mL, 12 mmol) and TBSOTf (2.1 mL, 9 mmol). The reaction 
mixture was then stirred for 12 h at 30 ºC. The reaction mixture 
was then poured onto saturated ammonium chloride and extracted 
several times with CH2Cl2. The organic layers were then dried 
over anhydrous Mg2SO4, filtered and evaporated under reduced 
pressure. The resulting oil was then subjected to column 
chromatography on silica gel (hexane) to yield 15 (1.55 g, 90%): 
oil, []D +4.9 (c 1; CHCl3); 1H NMR  6.20 (1H, dd, J = 17.5, 11 
Hz), 5.00 (1H, br d, J  17.5 Hz), 4.96 (1H, dd, J  11 Hz), 3.90 
(1H, d, J = 7.5 Hz), 3.75 (1H, d, J = 1 Hz), 2.07 (1H, br quint, J  
7 Hz), 1.94 (1H, br quint, J  7 Hz), 1.12 (3H, s), 1.10 (3H, s), 
0.99 (3H, d overlapped), 0.98 (9H, s), 0.96 (9H, s), 0.91 (3H, d, J 
= 7 Hz), 0.88 (3H, d, J = 7 Hz), 0.16 (3H, s), 0.12 (3H, s), 0.09 
(3H, s), 0.05 (3H, s); 13C NMR  42.8, 18.6, 18.5 (C), 146.5, 
80.7, 76.5, 45.2, 31.0 (CH), 110.0 (CH2), 26.7, 26.3 (x 3), 26.2 (x 
3), 25.8, 21.0, 16.2, 13.5, 2.9, 3.0, 4.3, 4.4 (CH3); HR ESMS 
m/z 451.3408 (M+Na+), calcd. for C24H52NaO2Si2, 451.3404. 
(ent-15): oil, []D 6.6 (c 1; CHCl3). Physical and spectral data 





tetramethyldec-1-en-4-ol (16) and (4R,6R,7R,8R)-6,8-bis 
(tert-butyldimethylsilyloxy)-5,5,7,9-tetramethyldec-1-en-4-
ol (18). Olefin 15 (1.29 g, 3 mmol) was dissolved in dry 
CH2Cl2 (60 mL) and cooled to 78C. A stream of ozone-
oxygen was bubbled through the solution until persistence of 
the bluish color. Dry N2 was then bubbled through the 
solution for 10 min. at the same temperature. After addition of 
PPh3 (1.18 g, 4.5 mmol), the solution was left to stir at room 
temperature for 2 h. Solvent removal under reduced pressure 
gave a solid material, which was put on the top of a short 
silica gel pad and rapidly washed with hexane-Et2O 99:1. 
After removal of volatiles under reduced pressure, the crude 
oily aldehyde was then directly used as such in the next 
allylation step (for weight calculations, the yield of the 
ozonolysis step was assumed to be quantitative). 
The oily material from above was dissolved under N2 in dry 
THF (15 mL) and cooled in an ice bath. After this, a 1 M 
solution of allylmagnesium bromide in THF (4 mL, 4 mmol) 
was added dropwise, and the mixture was allowed to reach 
room temperature, followed by stirring for 3 h (TLC 
monitoring). The reaction mixture was then poured onto 
saturated ammonium chloride and extracted several times with 
Et2O. The organic layers were then dried over anhydrous Na2SO4, 
filtered and evaporated under reduced pressure. The resulting oil 
was the subjected to a slow and careful chromatography on silica 
gel (hexane-Et2O, 99:1) to yield 16 (540 mg, 38%) and 18 (369 
mg, 26%). 
(16): oil, []D +5.5 (c 1; CHCl3); IR max (cm-1): 3480 (br, OH); 
1H NMR  5.85 (1H, ddt, J = 17, 10.5, 7 Hz), 5.20-5.15 (2H, m), 
3.92 (1H, d, J = 6 Hz), 3.87 (1H, d, J = 2 Hz), 3.65 (1H, d, J = 10 
Hz), 2.44 (1H, m), 2.20 (1H, m), 2.15-2.05 (2H, m), 1.95 (1H, br 
s, OH), 1.07 (3H, d, J = 7 Hz), 0.99 (3H, s), 0.95 (9H, s), 0.94 
(3H, s), 0.93 (9H, s), 0.91 (3H, d, J = 7 Hz), 0.89 (3H, d, J = 7 
Hz), 0.16 (3H, s), 0.11 (3H, s), 0.10 (3H, s), 0.08 (3H, s); 13C 
NMR  43.5, 18.8, 18.6 (C), 136.2, 80.7, 77.1, 75.1, 43.4, 30.8 
(CH), 118.2, 37.1 (CH2), 26.5 (x 3), 26.3 (x 3), 22.0, 21.1, 20.3, 
16.8, 14.3, 2.2, 3.3, 4.3, 4.4 (CH3); HR ESMS m/z 495.3667 
(M+Na+), calcd. for C26H56NaO3Si2, 495.3666. 
(ent-16): oil, []D 6.1 (c 1; CHCl3). Physical and spectral data 
identical to those of 16. 
(18): oil, []D +23.6 (c 1; CHCl3); IR max (cm-1): 3470 (br, OH); 
1H NMR  5.93 (1H, ddt, J = 17, 10.5, 7 Hz), 5.09 (1H, dm, J  
17 Hz), 5.05 (1H, dm, J  10.5 Hz), 4.35 (1H, br s, OH), 4.00 
(1H, dd, J = 10, 1.5 Hz), 3.92 (1H, d, J = 2 Hz), 3.86 (1H, dd, J = 
7.5, 1 Hz), 2.18 (1H, m), 2.10-2.00 (3H, m), 1.14 (3H, d, J = 7 
Hz), 1.04 (3H, s), 0.92 (24H, br s), 0.88 (3H, d, J = 7 Hz), 0.15 
(3H, s), 0.13 (3H, s), 0.12 (3H, s), 0.09 (3H, s); 13C NMR  42.6, 
18.8, 18.3 (C), 137.0, 83.7, 78.1, 76.1, 45.0, 31.5 (CH), 116.3, 
36.9 (CH2), 26.4 (x 3), 26.2 (x 3), 23.1, 21.8, 20.5, 16.4, 13.7, 
3.0, 3.4, 4.3 (x 2) (CH3); HR ESMS m/z 495.3666 (M+Na+), 
calcd. for C26H56NaO3Si2, 495.3666. 
(ent-18): oil, []D 16.6 (c 1; CHCl3). Physical and spectral data 
identical to those of 18. 
(4S,6R,7R,8R)-6,8-Bis(tert-butyldimethylsilyloxy)-5,5,7,9-
tetramethyldec-1-en-4-yl acrylate (17) and (4R,6R,7R,8R)-
6,8-bis(tert-butyldimethylsilyloxy)-5,5,7,9-tetramethyldec-
1-en-4-yl acrylate (19). Alcohol 16 or 18 (142 mg, 0.3 mmol) 
was dissolved under N2 in dry CH2Cl2 (5 mL), cooled to 78 
C and treated sequentially with ethyl N,N-diisopropylamine 
(160 L, 0.9 mmol) and acryloyl chloride (50 L, 0.6 mmol). 
The reaction mixture was then stirred for 3 h at 50C. The 
reaction mixture was then poured onto saturated ammonium 
chloride and extracted several times with CH2Cl2. The organic 
layers were then dried over anhydrous MgSO4, filtered and 
evaporated under reduced pressure. The resulting oil was the 
subjected in each case to chromatography on silica gel (hexane-
Et2O, 98:2) to afford, respectively, 17 (130 mg, 82%) and 19 (130 
mg, 82%), respectively. 
(17): oil, []D +10.9 (c 1; CHCl3); IR max (cm-1): 1727 (C=O); 
1H NMR  6.37 (1H, dd, J = 17.3, 1.5 Hz), 6.10 (1H, dd, J = 17.3, 
10.5 Hz), 5.80 (1H, dd, J = 10.5, 1.5 Hz), 5.74 (1H, dddd, J = 17, 
10, 8, 6 Hz), 5.30 (1H, dd, J = 10.5, 2.5 Hz), 5.03 (1H, dd, J = 17, 
1.5 Hz), 4.98 (1H, dd, J = 10, 1.5 Hz), 3.90 (1H, dd, J = 6.3, 1.5 
Hz), 3.77 (1H, d, J = 2.2 Hz), 2.68 (1H, m), 2.30-2.15 (2H, m), 
2.00 (1H, d quint, J = 7.5, 2.2 Hz), 1.07 (3H, d, J = 7.5 Hz), 1.04 
(3H, s), 0.99 (3H, s), 0.96 (9H, s), 0.93 (9H, s), 0.92 (3H, d, J = 7 
Hz), 0.90 (3H, d, J = 7 Hz), 0.15 (3H, s), 0.13 (6H, s), 0.10 (3H, 
s); 13C NMR  165.7, 43.9, 18.7, 18.6 (C), 135.2, 128.8, 79.7, 
77.4, 77.1, 43.9, 31.1 (CH), 130.1, 117.0, 35.8 (CH2), 26.5 (x 3), 
26.2 (x 3), 22.2, 21.4, 20.4, 17.2, 14.6, 2.5, 3.4, 4.2, 4.3 
(CH3); HR ESMS m/z 549.3774 (M+Na+), calcd. for 
C29H58NaO3Si2, 549.3771. 
(ent-17): oil, []D 6.3 (c 1; CHCl3). Physical and spectral data 
identical to those of 17. 
(19): oil, []D +9.1 (c 1; CHCl3); IR max (cm-1): 1728 (C=O); 1H 
NMR  6.40 (1H, dd, J = 17.3, 1.5 Hz), 6.13 (1H, dd, J = 17.3, 
10.5 Hz), 5.81 (1H, dd, J = 10.5, 1.5 Hz), 5.72 (1H, ddt, J = 17, 
10, 7 Hz), 5.21 (1H, dd, J = 10, 2.5 Hz), 5.03 (1H, dd, J = 17, 1.5 
Hz), 4.99 (1H, dd, J = 10, 1.5 Hz), 4.05 (1H, d, J = 5 Hz), 3.63 
(1H, d, J = 1.5 Hz), 2.34 (1H, hept, J = 7 Hz), 2.30-2.20 (2H, m), 
1.92 (1H, m), 1.13 (3H, d, J = 7.5 Hz), 1.03 (3H, s), 0.97 (3H, s), 
0.96 (9H, s), 0.94 (9H, s), 0.89 (3H, d, J = 7 Hz), 0.88 (3H, d, J = 
7 Hz), 0.17 (3H, s), 0.16 (3H, s), 0.15 (3H, s), 0.11 (3H, s); 13C 
NMR  165.7, 43.7, 19.0, 18.4 (C), 134.3, 128.8, 81.5, 76.9, 75.7, 
42.9, 30.4 (CH), 130.3, 117.5, 34.8 (CH2), 26.6 (x 3), 26.1 (x 3), 
22.9, 22.6, 20.1, 17.2, 14.8, 1.9, 3.7, 4.3, 4.7 (CH3); HR 
ESMS m/z 549.3774 (M+Na+), calcd. for C29H58NaO3Si2, 
549.3771. 
(ent-19): oil, []D 8.1 (c 1; CHCl3). Physical and spectral data 





(21). Diolefin 17 or 19 (105 mg, 0.2 mmol) was dissolved 
under N2 in dry, degassed toluene (20 mL) and treated with 
ruthenium catalyst Ru-I (16 mg, ca. 0.02 mmol). The mixture 
was heated at reflux until consumption of the starting material 
(ca. 4 h, TLC monitoring!). Removal of volatiles under 
reduced pressure and column chromatography of the residue 
on silica gel (hexane-Et2O 9:1) furnished the desired 
metathesis products 20 (94 mg, 94%) and 21 (98 mg, 98%), 
  
respectively. 
(20): off-white solid, mp 134-135 ºC (from Et2O-CH2Cl2), []D 
30.5 (c 1; CHCl3); IR max (cm-1): 1731 (C=O); 1H NMR  6.92 
(1H, ddd, J = 9.5, 6.3, 2.2 Hz), 6.01 (1H, dd, J = 9.5, 2 Hz), 4.55 
(1H, dd, J = 12.2, 4 Hz), 3.90 (1H, d, J = 2.5 Hz), 3.80 (1H, dd, J 
= 5.5, 1 Hz), 2.50-2.35 (2H, m), 2.20 (1H, br quint, J ~ 7 Hz), 
2.05 (1H, m), 1.12 (3H, s), 1.08 (3H, d, J = 7 Hz), 1.00 (3H, s), 
0.93 (9H, s), 0.90 (9H, s), 0.89 (3H, d, J = 7 Hz), 0.88 (3H, d, J = 
7 Hz), 0.14 (3H, s), 0.09 (3H, s), 0.04 (3H, s), 0.02 (3H, s); 13C 
NMR  164.4, 42.8, 18.8, 18.5 (C), 145.6, 121.3, 82.3, 79.3, 77.1, 
43.4, 30.9 (CH), 26.4 (x 3), 26.1 (x 3), 25.5, 22.1, 21.8, 19.8, 
17.2, 14.4, 2.4, 3.5, 4.3, 4.4 (CH3); HR ESMS m/z 521.3451 
(M+Na+), calcd. for C27H54NaO4Si2, 521.3458. 
(ent-20): oil, []D +31.1 (c 1; CHCl3). Physical and spectral data 
identical to those of 20. 
The stereostructures of 20 and ent-20 have been secured by 
means of an X-ray diffraction analysis.24 
(21): oil, []D +16.8 (c 1; CHCl3); IR max (cm-1): 1737 (C=O); 
1H NMR  6.89 (1H, ddd, J = 9.5, 6.5, 2 Hz), 5.98 (1H, dd, J = 
9.5, 2 Hz), 4.45 (1H, dd, J = 13, 3.5 Hz), 4.09 (1H, d, J = 2.5 Hz), 
3.88 (1H, dd, J = 5.5, 1 Hz), 2.33 (1H, ddt, J = 18, 13, 2.5 Hz), 
2.25-2.15 (2H, m), 1.93 (1H, m), 1.08 (3H, d, J = 7.5 Hz), 1.02 
(3H, s), 0.92 (3H, s), 0.89 (9H, s), 0.86 (9H, s, overlapping two 
methyl doublets), 0.12 (3H, s), 0.05 (3H, s), 0.03 (3H, s), 0.005t 
(3H, s); 13C NMR  164.4, 42.7, 18.8, 18.4 (C), 145.6, 121.2, 
80.6, 76.8, 76.3, 43.5, 30.6 (CH), 26.4 (x 3), 26.1 (x 3), 24.0, 
22.2, 19.7, 18.6, 17.0, 14.4, 2.3, 3.6, 4.5, 4.8 (CH3); HR 
ESMS m/z 521.3456 (M+Na+), calcd. for C27H54NaO4Si2, 
521.3458. 
(ent-21): oil, []D −18.2 (c 1; CHCl3). Physical and spectral data 
identical to those of 21. 
(3S,5R,6R,7R)-5,7-bis(tert-Butyldimethylsilyloxy)-4,4,6,8-
tetramethylnon-1-en-3-ol (24) and (3R,5R,6R,7R)-5,7-
bis(tert-butyldimethylsilyloxy)-4,4,6,8-tetramethylnon-1-
en-3-ol (26). Olefin 15 was subjected to the same sequence of 
ozonolysis followed by addition of vinylmagnesium chloride 
performed with 6. Work-up and careful chromatography on 
silica gel (hexane-Et2O, 99:1) afforded 24 (26%) and 26 (24%). 
(24): oil, []D 15 (c 1; CHCl3); IR max (cm-1): 3460 (br, OH); 
1H NMR  5.95 (1H, ddd, J = 17, 10, 6.5 Hz), 5.26 (1H, br dt, J  
17, 1.5 Hz), 5.20 (1H, br dt, J ~ 10, 1.5 Hz), 4.14 (1H, dt, J = 6.5, 
1.5 Hz), 4.01 (1H, d, J = 2.5 Hz), 3.89 (1H, dd, J = 10, 1.5 Hz), 
2.50 (1H, br s, OH), 2.10 (2H, m), 1.05 (3H, d, J = 7 Hz), 0.99 
(3H, s), 0.94 (9H, s), 0.93 (9H, s, overlapping a methyl doublet), 
0.90 (3H, s), 0.89 (3H, d, J = 7 Hz), 0.17 (3H, s), 0.14 (6H, s), 
0.09 (3H, s); 13C NMR  43.4, 18.7, 18.6 (C), 138.0, 80.3, 79.6, 
77.8, 44.7, 31.3 (CH), 116.7 (CH2), 26.3 (x 6), 21.1, 21.0, 19.9, 
16.6, 13.8, 2.5, 3.0, 4.3 (x 2) (CH3); HR ESMS m/z 481.3513 
(M+Na+), calcd. for C25H54NaO3Si2, 481.3509. 
(ent-24): oil, []D +19.3 (c 1; CHCl3). Physical and spectral data 
identical to those of 24. 
(26): oil, []D +8.9 (c 1; CHCl3); IR max (cm-1): 3450 (br, OH); 
1H NMR  5.84 (1H, ddd, J = 17, 10.5, 6.5 Hz), 5.26 (1H, br ddd, 
J  17, 2, 1.5 Hz), 5.15 (1H, br ddd, J ~ 10, 2, 1.5 Hz), 4.70 (1H, 
br s, OH), 4.46 (1H, d, J = 6.5 Hz), 4.01 (1H, d, J = 2.2 Hz), 3.87 
(1H, dd, J = 8.2, 1.5 Hz), 2.08 (1H, d quint, J = 8, 2 Hz), 2.02 
(1H, d quint, J = 7, 1.5 Hz), 1.16 (3H, d, J = 7.5 Hz), 1.04 (3H, s), 
0.95 (3H, d, J = 7 Hz), 0.94 (9H, s), 0.93 (9H, s), 0.91 (3H, s), 
0.90 (3H, d, J = 7 Hz), 0.16 (3H, s), 0.15 (3H, s), 0.14 (3H, s), 
0.10 (3H, s); 13C NMR  42.3, 18.8, 18.3 (C), 137.9, 83.1, 78.5, 
78.2, 45.3, 31.6 (CH), 116.6 (CH2), 26.4 (x 3), 26.1 (x 3), 23.2, 
22.2, 20.2, 16.3, 13.3, 2.8, 3.4, 4.3, 4.4 (CH3); HR ESMS 
m/z 481.3506 (M+Na+), calcd. for C25H54NaO3Si2, 481.3509.  
(ent-26): oil, []D 8.1 (c 1; CHCl3). Physical and spectral data 
identical to those of 26. 
(3S,5R,6R,7R)-5,7-Bis(tert-butyldimethylsilyloxy)-4,4,6,8-
tetramethylnon-1-en-3-yl acrylate (25) and (3R,5R,6R,7R)-
5,7-bis(tert-butyldimethylsilyloxy)-4,4,6,8-tetramethylnon-
1-en-3-yl acrylate (27). Alcohol 24 or 26 were subjected to 
esterification with acryloyl chloride under the same conditions 
as for the preparation of 17 and 19. Work-up and column 
chromatography on silica gel (hexane-Et2O, 98:2) furnished 
respectively, 25 (85%) and 27 (83%). 
(25): oil, []D 14.2 (c 1; CHCl3); IR max (cm-1): 1732 (C=O); 
1H NMR  6.40 (1H, dd, J = 17.3, 1.5 Hz), 6.14 (1H, dd, J = 17.3, 
10.5 Hz), 5.92 (1H, ddd, J = 17.3, 10.5, 6.2 Hz), 5.82 (1H, dd, J = 
10.5, 1.5 Hz), 5.43 (1H, d, J = 6.2 Hz), 5.30-5.20 (2H, m), 3.93 
(1H, d, J = 5.5 Hz), 3.78 (1H, d, J = 2 Hz), 2.25 (1H, hept, J = 7 
Hz), 1.93 (1H, m), 1.06 (3H, d, J = 7 Hz), 1.05 (3H, s), 1.00 (3H, 
s), 0.96 (9H, s), 0.92 (9H, s), 0.91 (3H, d, J = 7 Hz), 0.89 (3H, d, 
J = 7 Hz), 0.15 (3H, s), 0.13 (3H, s), 0.12 (3H, s), 0.10 (3H, s); 
13C NMR  164.9, 43.3, 18.9, 18.5 (C), 133.7, 128.7, 79.7, 78.9, 
76.7, 43.4, 30.9 (CH), 130.3, 118.2 (CH2), 26.5 (x 3), 26.2 (x 3), 
22.0 (x 2), 20.1, 17.3, 14.7, 2.2, 3.6, 4.2, 4.4 (CH3); HR 
ESMS m/z 535.3618 (M+Na+), calcd. for C28H56NaO4Si2, 
535.3615. 
(ent-25): oil, []D +13.3	(c 1; CHCl3). Physical and spectral data 
identical to those of 25. 
(27): oil, []D +26.5 (c 1; CHCl3); IR max (cm-1): 1731 (C=O); 
1H NMR  6.38 (1H, dd, J = 17.3, 1.5 Hz), 6.15 (1H, dd, J = 17.3, 
10.5 Hz), 5.83 (1H, dd, J = 10.5, 1.5 Hz), 5.77 (1H, ddd, J = 17.3, 
10.5, 6.2 Hz), 5.37 (1H, d, J = 6.2 Hz), 5.30-5.20 (2H, m), 3.97 
(1H, d, J = 6 Hz), 3.70 (1H, d, J = 2 Hz), 2.28 (1H, hept, J = 7 
Hz), 2.00 (1H, m), 1.09 (3H, d, J = 7 Hz), 1.04 (3H, s), 0.99 (3H, 
s), 0.96 (9H, s), 0.93 (9H, s), 0.90 (3H, d, J = 7 Hz), 0.89 (3H, d, 
J = 7 Hz), 0.13 (6H, s), 0.11 (3H, s), 0.06 (3H, s); 13C NMR  
165.3, 43.3, 19.0, 18.5 (C), 132.9, 128.9, 79.4, 78.7, 76.2, 43.5, 
30.5 (CH), 130.4, 119.1 (CH2), 26.6 (x 3), 26.1 (x 3), 22.6, 21.6, 
19.4, 17.2, 14.5, 2.2, 3.5, 4.5, 4.8 (CH3); HR ESMS m/z 
535.3613 (M+Na+), calcd. for C28H56NaO4Si2, 535.3615. 
(ent-27): oil, []D 28.4 (c 1; CHCl3). Physical and spectral data 
identical to those of 27. 
The stereostructure of ent-27 has been secured by means of an X-
ray diffraction analysis.24 
(5S)-[(3R,4R,5R)-3,5-Bis(tert-butyldimethylsilyloxy)-2,4,6-
trimethylheptan-2-yl]furan-2(5H)-one (28) and (5R)-
[(3R,4R,5R)-3,5-Bis(tert-butyldimethylsilyloxy)-2,4,6-
trimethylheptan-2-yl]furan-2(5H)-one (29). Diolefin 25 or 
27 (102 mg, 0.2 mmol) was dissolved under N2 in dry, 
degassed toluene (25 mL) and treated with Hoveyda-Grubbs 
  
ruthenium catalyst Ru-III (12 mg, ca. 0.02 mmol). The 
mixture was heated at 80 ºC until consumption of the starting 
material (ca. 4 h, TLC monitoring!). Removal of volatiles 
under reduced pressure and column chromatography of the 
residue on silica gel (hexane-Et2O 9:1) furnished the desired 
metathesis products 28 (75 mg, 78%) and 29 (77 mg, 80%), 
respectively. 
(28): oil, []D 42 (c 1; CHCl3); IR max (cm-1): 1763 (C=O); 1H 
NMR  7.62 (1H, dd, J = 6, 1.5 Hz), 6.12 (1H, dd, J = 6, 2 Hz), 
5.25 (1H, dd, J = 2, 1.5 Hz), 3.95 (1H, d, J = 2.5 Hz), 3.80 (1H, 
dd, J = 7.5, 2 Hz), 2.08 (2H, m), 1.08 (3H, d, J = 7.5 Hz), 1.05 
(3H, s), 0.95 (3H, d, J = 7 Hz), 0.93 (9H, s), 0.92 (9H, s), 0.94 
(3H, s), 0.90 (3H, d, J = 7 Hz), 0.15 (3H, s), 0.11 (3H, s), 0.10 
(3H, s), 0.07 (3H, s); 13C NMR  173.1, 44.7, 18.7, 18.5 (C), 
155.8, 121.8, 87.7, 78.3, 77.8, 45.3, 31.5 (CH), 26.3 (x 3), 26.2 (x 
3), 22.4, 20.3 (x 2), 16.8, 13.8, 2.8, 3.1, 4.3, 4.4 (CH3); HR 
ESMS m/z 507.3296 (M+Na+), calcd. for C26H52NaO4Si2, 
507.3302. 
(ent-28): oil, []D +44.5 (c 1; CHCl3). Physical and spectral data 
identical to those of 28. 
(29): oil, []D +34.5 (c 1; CHCl3); IR max (cm-1): 1763 (C=O); 
1H NMR  7.46 (1H, dd, J = 6, 1.5 Hz), 6.15 (1H, dd, J = 6, 2.2 
Hz), 5.10 (1H, dd, J = 2.2, 1.5 Hz), 4.14 (1H, d, J = 2.5 Hz), 3.80 
(1H, dd, J = 7, 1.5 Hz), 2.13 (1H, d quint, J = 7, 1.5 Hz), 1.98 
(1H, d quint, J = 7.5, 2.5 Hz), 1.09 (3H, s), 1.07 (3H, d, J = 7.5 
Hz), 0.92 (3H, d, J = 7 Hz), 0.91 (9H, s), 0.90 (9H, s), 0.89 (3H, 
d, J = 7 Hz), 0.82 (3H, s), 0.17 (3H, s), 0.13 (3H, s), 0.12 (3H, s), 
0.05 (3H, s); 13C NMR  173.0, 44.4, 18.8, 18.7 (C), 155.0, 
123.1, 87.8, 77.5, 77.0, 45.0, 31.5 (CH), 26.5 (x 3), 26.4 (x 3), 
21.2, 20.2, 18.1, 17.2, 14.1, 2.6, 3.1, 4.1, 4.3 (CH3); HR 
ESMS m/z 507.3304 (M+Na+), calcd. for C26H52NaO4Si2, 
507.3302. 
(ent-29): oil, []D 36.6 (c 1; CHCl3). Physical and spectral data 
identical to those of 29. 
Biological procedures 
Cell culture 
Cell culture media were purchased from Gibco (Grand Island, 
NY, USA). Fetal bovine serum (FBS) was a product of Harlan-
Seralab (Belton, U.K.). Supplements and other chemicals not 
listed in this section were obtained from Sigma Chemicals Co. 
(St. Louis, Mo., USA). Plastics for cell culture were supplied by 
Thermo ScientificTM BioLite. All tested compounds were 
dissolved in DMSO at a concentration of 10 g/mL and stored at 
–20C until use. 
Cell lines were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) containing glucose (1 g/L), glutamine (2 mM), 
penicillin (50 U/mL), streptomycin (50 µg/mL) and amphotericin 
B (1.25 µg/mL), supplemented with 10% FBS. 
Cytotoxicity assays 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromi-
de (MTT; Sigma Chemical Co., St. Louis, MO) dye reduction 
assay in 96-well microplates was used, as previously described.25 
Some 5 x 103 cells of HT-29, HTC-116, MCF-7 and HL-60 and 
2.5 x 103 cells of HEK-293 and Hela cells in a total volume of 
100 µL of their respective growth media were incubated with 
serial dilutions of the tested compounds. After 2 days of 
incubation (37 C, 5% CO2 in a humid atmosphere), 10 µl of 
MTT (5 mg/ml in PBS) were added to each well and the plate 
was incubated for further 4 h (37 C). The resulting formazan was 
dissolved in 150 µL of 0.04 N HCl/2-propanol and read at 550 
nm. All determinations were carried out in triplicate. 
Tubulin polymerization 
Tubulin polymerization was carried out in a 96 well plate. In 
each well 50 µL of a solution of 25 µM of tubulin in GAB buffer 
was added to 50 µL of 27.5 µM solution of the corresponding 
compounds in GAB buffer (20 mM sodium phosphate, 10 mM 
MgCl2, 1 mM EGTA, 30% glycerol) and 0.1 mM GTP at pH = 
6.5. Then, the plate was incubated at 37 ºC in Multiskan (R) and 
absorbance at 340 nM was registered every 30 seconds during 2 
hours. 
ELISA analysis 
HT-29 cells at 70–80% confluence were collected and 1.5 x 105 
cells were placed in a six well plate in 1.5 mL of medium. After 
24h, cells were incubated with the corresponding compounds for 
72 h. Culture supernatants were collected and VEGF secreted by 
HT-29 cells was determined using Invitrogen Human Vascular 
Endothelial Growth Factor ELISA Kit according to the 
manufacturer’s instructions. 
RT-qPCR analysis 
HT-29 cells at 70–80% confluence were collected and 1.5 x 105 
cells were placed in a six well plate in 1.5 mL of medium. After 
24h, cells were incubated with the corresponding compounds for 
72 h. Cells were collected and the total cellular RNA from HT-29 
cells was isolated using Ambion RNA extraction Kit according to 
the manufacturer’s instructions. The cDNA was synthesized by 
MMLV-RT with 1–21 g of extracted RNA and oligo(dT)15 
according to the manufacturer’s instructions. 
Genes were amplified by use of a thermal cycler and 
StepOnePlus ™ Taqman ® probes. TaqMan ® Gene Expression 
Master Mix Fast containing the appropriate buffer for the 
amplification conditions, dNTPs, thermostable DNA polymerase 
enzyme and a passive reference probe was used. To amplify each 
of the genes the predesigned primers were used and sold by Life 
Technologies TaqMan ® Gene Expression Assays, Hs99999903-
m1 (-actin), Hs00900055-m1 (VEGF), Hs00972646-m1 
(hTERT) y Hs00153408-m1 (c-Myc). 
Acknowledgments 
Financial support has been granted to M. C. by the Spanish 
Government (Ministerio de Economía y Competitividad of Spain, 
project CTQ2014-52949-P), by the Consellería d’Empresa, 
Universitat i Ciencia de la Generalitat Valenciana (project 
PROMETEO/2013/027) and by the University Jaume I (project 




1 D. Hanahan and R. A. Weinberg, Cell, 2011, 144, 646-674. 
2 F. Torres-Andón and B. Fadeel, Acc. Chem. Res., 2013, 46, 733-742. 
3 T. Fojo (Ed.), The Role of Microtubules in Cell Biology, 
Neurobiology and Oncology, Humana Press, Totowa, NJ, 2008. 
4 G. M. Alushin, G. C. Lander, E. H. Kellogg, R. Zhang, D. Baker, E. 
Nogales, Cell, 2014, 157, 1117-1129. 
5 (a) T. Beckers and S. Mahboobi, Drugs Fut., 2003, 28, 767-785. (b) 
J. A. Hadfield, S. Ducki, N. Hirst and A. T. McGown, Progr. Cell 
Cycle Res., 2003, 5, 309-325. (c) M. A. Jordan and L. Wilson, Nat. 
  
Rev. Cancer, 2004, 4, 253-265. (d) S.-H. Chen and J. Hong, Drugs 
Fut., 2006, 31, 123-150. (e) E. Pasquier and M. Kavallaris, IUBMB 
Life, 2008, 60, 165-170. (f) P. Singh, K. Rathinasamy, R. Mohan and 
D. Panda, IUBMB Life, 2008, 60, 368-375.  (g) P. G. Morris and M. 
N. Fornier, Clin. Cancer Res., 2008, 14, 7167-7172. (h) E. A. Perez, 
Mol. Cancer Ther., 2009, 8, 2086-2095. (i) S. M. Chen, L.-H. Meng 
and J. Ding, Expert Opin. Invest. Drugs, 2010, 19, 329-343. (j) D. 
Calligaris, P. Verdier-Pinard, F. Devred, C. Villard, D. Braguer and 
D. Lafitte, Cell. Mol. Life Sci., 2010, 67, 1089-1104. 
6 (a) K.-H. Altmann and J. Gertsch, Nat. Prod. Rep., 2007, 24, 327-
357.  (b) D. G. I. Kingston, J. Nat. Prod., 2009, 72, 507-515. 
7 J. Chen, T. Liu, X. Dong and Y. Hu, Mini-Rev. Med. Chem., 2009, 9, 
1174-1190. 
8 Y. Fu, S. Li, Y. Zu, G. Yang, Z. Yang, M. Luo, S. Jiang, M. Wink 
and T. Efferth, Curr. Med. Chem., 2009, 16, 3966-3985. 
9 F. Sarabia, M. García-Castro and A. Sánchez-Ruiz, Curr. Bioact. 
Comp., 2006, 2, 269-299. 
10 T. Usui, H. Watanabe, H. Nakayama, Y. Tada, N. Kanoh, M. 
Kondoh, T. Asao, K. Takio, H. Watanabe, K. Nishikawa, T. Kitahara 
and H. Osada, Chem. & Biol., 2004, 11, 799-806. 
11 (a) K. Yasui, Y. Tamura, K. Nakatani, K. Kawada and M. Ohtani, J. 
Org. Chem., 1995, 60, 7567-7574. (b) M. K. Gurjar, J. T. Henri, Jr., 
D. S. Bose and A. V. R. Rao, Tetrahedron Lett., 1996, 37, 6615-
6618. (c) N. Chida, M. Yoshinaga, T. Tobe and S. Ogawa, Chem. 
Comm., 1997, 1043-1044. (d) H. Watanabe, H. Watanabe, M. Bando, 
M. Kido and T. Kitahara, Tetrahedron, 1999, 55, 9755-9776. (e) G. 
E. Keck, C. E. Knutson and S. A. Wiles, Org. Lett., 2001, 3, 707-710.  
(f) L. C. Dias, L. G. de Oliveira and M. A. de Sousa, Org. Lett., 2003, 
5, 265-268. (g) X. Shen, A. S. Wasmuth, J. Zhao, C. Zhu and S. G. 
Nelson, J. Am. Chem. Soc., 2006, 128, 7438-7439. (h) D. Enders, S. 
Dhulut, D. Steinbusch and A. Herrbach, Chem. Eur. J., 2007, 13, 
3942-3949. (i) C. Bressy, J.-P. Vors, S. Hillebrand, S. Arseniyadis 
and J. Cossy, Angew. Chem. Int. Ed., 2008, 47, 10137-10140.  (j) M. 
T. Crimmins and A.-M. R. Dechert, Org. Lett., 2009, 11, 1635-1638. 
12 For two comprehensive, recent reviews, see: (a) J. A. Marco, M. 
Carda, J. Murga and E. Falomir, Tetrahedron, 2007, 63, 2929-2958. 
(b) J. A. Marco and M. Carda, Recent advances in the field of 
naturally occurring 5,6-dihydropyran-2-ones, in Natural Lactones 
and Lactams. Synthesis, Occurrence and Biological Activity, T. 
Janecki (Ed.), Wiley-VCH, 2014, pp. 51-100. For pironetin tubulin 
binding site: (a) J. Yang, Y. Wang, T. Wang, J. Jiang, C. H. Botting, 
H. Liu, Q. Chen, J. Yang, J. H. Naismith, X. Zun and L. Chen, 
Nature Communicantions, 2016, 7, doi:10.1038/ncomms12103. (b)  
A. E Prota,. J. Setter, A. B Waight, K. Bargsten, J. Murga, J. F. Diaz 
and M. O. Steinmetz, Journal of Molecular Biology, 2016, doi: 
10.1016/j.jmb.2016.06.023. 
13 J. A. Marco, J. García-Pla, M. Carda, J. Murga, E. Falomir, C. Trigili, 
S. Notararigo, J. F. Díaz and I. Barasoain, Eur. J. Med. Chem., 2011, 
46, 1630-1637. 
14 J. Paños, S. Díaz-Oltra, M. Sánchez-Peris, J. García-Pla, J. Murga, E. 
Falomir, M. Carda, M. Redondo-Horcajo, J. F. Díaz, I. Barasoain and 
J. A. Marco, Org. Biomol. Chem. 2013, 11, 5809-5826. 
15 R. W. Hoffmann, Chem. Rev., 1989, 89, 1841-1860. 
16 For two interesting reviews on the conformational aspects of open-
chain carbon backbones, see: (a) R. W. Hoffmann, M. Stahl, U. 
Schopfer and G. Frenking, Chem. Eur. J., 1998, 4, 559-566. (b) R. 
W. Hoffmann, Angew. Chem. Int. Ed., 2000, 39, 2054-2070. 
17 J. Welti, S. Loges, S. Dimmeler and P. Carmeliet, J. Clin. Invest. 
2013, 123, 3190-3200. 
18 C. Yinnan and Z. Yanmin Z., Pharmacol. Ther., 2016, 163, 24-47. 
19 (a) H. Huang, H. Weng, H. Zhou and L. Qu, Curr. Pharm. Des., 
2014, 20, 6543-6554. (b) B.-J. Chen, Y.-L. Wu, Y. Tanaka and W. 
Zhang, Int. J. Biol. Sci., 2014, 10, 1084-1096. 
20 This corresponds to the concept of polypharmacology: J.-U. Peters, J. 
Med. Chem. 2013, 56, 8955-8971. 
21 S. Källström, A. Erkkilä, P. M. Pihko, R. Sjöholm, R. Sillanpää and 
R. Leino, Synlett, 2005, 751-756. In order to work efficiently at a 
much higher scale than in the original paper, the experimental 
procedure had to be carried out as described in the Experimental. 
22 For recent reviews on metathesis, see: (a) J. Cossy, S. Arseniyadis 
and C. Meyer (Eds.), Metathesis in Natural Product Synthesis, 
Wiley-VCH, Weinheim, 2010. (b) A. H. Hoveyda, J. Org. Chem., 
2014, 79, 4763-4792. 
23 In some cases, products from intramolecular Michael addition of one 
hydroxyl group in the side chain to the conjugated C=C bond were 
detected. 
24 The crystal structures have been deposited at the Cambridge 
Crystallographic Data Centre and allocated the following deposition 
numbers: 2 (CCDC-1431101), ent-2 (CCDC-1431108), 4 (CCDC-
1431102), ent-4 (CCDC-1431106), 5 (CCDC-1431104), ent-5 
(CCDC-1431105), 20 (CCDC-1431103), ent-20 (CCDC-1431107) 
and ent-27 (CCDC-1431109). 
25 S. Rodríguez-Nieto, M. A. Medina and A. R. Quesada, Anticancer 
Res. 2001, 21, 3457-3460. 
